JW Jungwooje Yak 'Hemlibra' Proven to Improve Quality of Life for Severe Hemophilia A Patients

JW Pharmaceutical's hemophilia treatment 'Hemlibra'. Photo by JW Pharmaceutical

JW Pharmaceutical announced on the 31st that research results showing a significant improvement in the quality of life of severe hemophilia A patients treated with their supplied hemophilia treatment 'Hemlibra' were presented at the 'European Association for Haemophilia and Allied Disorders Annual Meeting (EAHAD 2025)'.

EAHAD is an international academic event that shares the latest research and treatments in the field of hemophilia and other bleeding disorders. The event, held over three days from the 5th of last month in Milan, Italy, was attended by medical professionals, researchers, and patient organizations from around the world to exchange knowledge and experiences related to these disorders.

This study was led by Professor Jan Astermark and his research team from the Department of Translational Medicine at Lund University in Sweden. The team analyzed changes in quality of life and bleeding after administering Hemlibra for 48 weeks to a total of 28 severe hemophilia A patients (16 adults and 12 adolescents) who had previously been on prophylactic treatment using factor VIII products for more than 24 weeks.

The results showed that after Hemlibra administration, physical activity levels and joint health were stably maintained, and bleeding occurrences were significantly reduced.

Using tools to assess the quality of life of hemophilia patients, the survey found that concerns and discomfort related to bleeding during daily life and social and leisure activities generally decreased. In particular, 55.7% of adults and 33.4% of adolescents responded that the treatment had become more convenient.

In the survey, 92% of participants (23 out of 25) preferred Hemlibra treatment over the previous factor VIII products, citing reasons such as 'reduced frequency of administration (69.6%)', 'improved quality of life (43.5%)', and 'more convenient administration method (34.8%)'.

Not only the quality of life but also the bleeding suppression effect was remarkable. The number of patients who did not experience bleeding requiring treatment during various physical activities increased from 11 when using factor VIII products to 21 after switching to Hemlibra, nearly doubling. Additionally, the number of patients with no bleeding or no bleeding requiring treatment of any type increased after Hemlibra administration.

Joint health was also stable. No new joint damage occurred, and patients' joint conditions were generally maintained without change. Furthermore, Hemlibra demonstrated excellent safety results. Some patients experienced injection site reactions, headaches, and fatigue, but no new adverse effects were reported.

The research team explained, "This study shows that Hemlibra can provide better effects not only in bleeding management compared to existing factor VIII prophylaxis but also in treatment convenience and maintaining patients' daily lives."

A JW Pharmaceutical representative said, "This study is significant in confirming that Hemlibra is not just a simple drug switch but a treatment option that can bring real changes to patients' daily lives," adding, "We hope Hemlibra will establish itself as a more effective and convenient treatment for hemophilia A patients."

This content was produced with the assistance of AI translation services.